Focus: Fate Therapeutics is a public biotech company specializing in stem cell-modulating therapeutics and cell therapy, headquartered in San Diego with a focus on allogeneic cell therapies for oncology and hematologic malignancies.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Best suited for scientists and clinical professionals seeking high-impact cell therapy development with moderate financial risk; less ideal for those requiring near-term revenue upside or clinical milestone visibility.
Help build intelligence for Fate Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Fate Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Fate Therapeutics Advances Off-the-Shelf CAR T-Cell Therapies for Autoimmune Diseases and Cancer – Clinical Pipeline and 2026 Updates - minichart.com.sg
Fate Therapeutics Advances Off-the-Shelf CAR T-Cell Therapies for Autoimmune Diseases and Cancer – Clinical Pipeline and 2026 Updates minichart.com.sg
Fate Therapeutics (NASDAQ: FATE) details FT819, FT836 data and cash runway into 2028 - Stock Titan
Fate Therapeutics (NASDAQ: FATE) details FT819, FT836 data and cash runway into 2028 Stock Titan
Fate Therapeutics to present CAR T-cell data at medical conferences - Investing.com UK
Fate Therapeutics to present CAR T-cell data at medical conferences Investing.com UK
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases - The Manila Times
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases The Manila Times
Fate Therapeutics Announces Presentations at 2026 ASCO and - GlobeNewswire
Fate Therapeutics Announces Presentations at 2026 ASCO and GlobeNewswire
Off-the-shelf CAR T trials in cancer and autoimmune at 2026 ASCO, EULAR - Stock Titan
Off-the-shelf CAR T trials in cancer and autoimmune at 2026 ASCO, EULAR Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo